NVAX Novavax (NVAX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001000694
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
121
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · no price filed
Novavax insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for NOVAVAX INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Dec 24, 2024.
- The trade is 10.4% of the 51,760 shares held after it.
- 1 other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YOUNG JAMES F sold about $43.2K of NVAX on Dec 31, 2024; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 21, 2024.
- The trade is 8.0% of the 57,160 shares held after it.
- 1 other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YOUNG JAMES F sold about $39.0K of NVAX on Dec 24, 2024; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 28.1% of the 14,770 shares held after it.
- 1 other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director King Rachel K. sold about $37.4K of NVAX on Dec 13, 2024; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 18, 2024.
- The trade is 12.1% of the 61,760 shares held after it.
- 1 other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YOUNG JAMES F sold about $105.7K of NVAX on Jun 21, 2024; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 31, 2022.
- The trade is 9.1% of the 70,367 shares held after it.
- 1 other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YOUNG JAMES F sold about $87.1K of NVAX on Jun 18, 2024; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.475 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
121 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
+64.7% year over year
more than 80% of Pharma & Biotech
Margin
39.2% net margin
more than 93% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
31.5% of the float short (float per yahoo 2026-10-26) · 8.1 days to cover · settled 2026-09-30
more than 99% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NVAX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.4%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NVAX: institutional holders (13F)
13F holdings, latest reported quarter
14,165,577 sh
$133.4M
13,946,881 sh
$131.4M
11,740,550 sh
$110.6M
7,607,996 sh
$71.7M
7,257,449 sh
$68.4M
Congress trades in NVAX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NVAX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NVAX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$2.5M position · as of 2026-07-31
1.3%
ALPS Medical Breakthroughs ETF
$1.8M position · as of 2026-05-31
1.1%
Virtus Biotech Etf
$1.1M position · as of 2026-07-31
1.1%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$70.9M position · as of 2026-06-30
0.7%
PROFUND VP BIOTECHNOLOGY
$313.6K position · as of 2026-06-30
0.6%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$523.7K position · as of 2026-07-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
21 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
0 active
10
Phase 3
0 active
2
Phase 4
0 active
7
Multi-phase
0 active
What changed recently
Efficacy and Safety of NVX-CoV2705
2026-10-24 · Active Not Recruiting → Terminated · The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. The decision was made in consultation with FDA/CBER and was unrelated to safety concerns.
Phase 4
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Stanley C. Erck
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.9M
$6.3M
$2.7M
-94%
-15%
2024
$5.1M
$7.1M
$1.5M
-93%
-40%
2022
$8.4M
-$36.6M
$3.3M
-91%
-50%
2021
$1.1M
$43.6M
$1.5M
+28%
-30%
2020
$48.1M
$84.8M
$17.1M
+2702%
+55%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 121 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NVAX financials
Revenue growth
+64.7%
XBRL, annual
Net margin
39.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$413.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NVAX
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $682.2M |
| FY Dec 2023 | $983.7M |
| FY Dec 2022 | $2.0B |
| FY Dec 2021 | $1.1B |
| Jun 2026 | $56.7M |
| Mar 2026 | $139.5M |
| Dec 2025 | $147.1M |
| Sep 2025 | $70.4M |
| Jun 2025 | $239.2M |
| Mar 2025 | $666.7M |
| Dec 2024 | $88.3M |
| Sep 2024 | $84.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-59.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NVAX
| FY Dec 2025 | +39.2% |
| FY Dec 2024 | -27.5% |
| FY Dec 2023 | -55.4% |
| FY Dec 2022 | -33.2% |
| FY Dec 2021 | -152.1% |
| Jun 2026 | -94.2% |
| Mar 2026 | -6.8% |
| Dec 2025 | +11.9% |
| Sep 2025 | -287.3% |
| Jun 2025 | +44.5% |
| Mar 2025 | +77.8% |
| Dec 2024 | -91.8% |
| Sep 2024 | -143.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$42.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NVAX
| FY Dec 2025 | -$250.2M |
| FY Dec 2024 | -$100.3M |
| FY Dec 2023 | -$767.7M |
| FY Dec 2022 | -$505.0M |
| FY Dec 2021 | $265.5M |
| Jun 2026 | -$73.4M |
| Mar 2026 | -$33.7M |
| Dec 2025 | -$41.6M |
| Sep 2025 | $106.4M |
| Jun 2025 | -$128.0M |
| Mar 2025 | -$187.1M |
| Dec 2024 | -$175.1M |
| Sep 2024 | -$146.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity NVAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.13x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt NVAX
| FY Dec 2025 | -1.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.13x |
| Mar 2026 | -0.31x |
| Dec 2025 | -1.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity NVAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -1,266% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-21.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NVAX
| FY Dec 2025 | +32.2% |
| FY Dec 2024 | -11.2% |
| FY Dec 2023 | -26.9% |
| FY Dec 2022 | -27.2% |
| FY Dec 2021 | -83.8% |
| Jun 2026 | -21.6% |
| Mar 2026 | -7.5% |
| Dec 2025 | +32.2% |
| Sep 2025 | +23.6% |
| Jun 2025 | +26.8% |
| Mar 2025 | +36.2% |
| Dec 2024 | -11.2% |
| Sep 2024 | -16.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NVAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-29.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NVAX
| FY Dec 2025 | +80.7% |
| FY Dec 2024 | -87.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -283.6% |
| Jun 2026 | -29.8% |
| Mar 2026 | -9.9% |
| Dec 2025 | +80.7% |
| Sep 2025 | +48.0% |
| Jun 2025 | +43.7% |
| Mar 2025 | +57.9% |
| Dec 2024 | -87.6% |
| Sep 2024 | -83.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NVAX
| FY Dec 2025 | 2.86x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 2.86x |
| Sep 2025 | 4.87x |
| Jun 2025 | 2.78x |
| Mar 2025 | 2.43x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.7B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value NVAX
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.1B |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-2.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield NVAX
| FY Dec 2025 | -22.9% |
| FY Dec 2024 | -7.8% |
| FY Dec 2023 | -134.6% |
| FY Dec 2022 | -62.6% |
| FY Dec 2021 | +2.5% |
| Jun 2026 | -2.7% |
| Mar 2026 | -7.3% |
| Dec 2025 | -22.9% |
| Sep 2025 | -27.3% |
| Jun 2025 | -62.4% |
| Mar 2025 | -19.1% |
| Dec 2024 | -7.8% |
| Sep 2024 | -5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NVAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.1B | $682.2M | $983.7M | $2.0B |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M |
| Net income | $440.3M | -$187.5M | -$545.1M | -$657.9M |
| EPS (diluted) | 2.58 | -1.23 | -5.41 | -8.42 |
| Operating cash flow | -$244.6M | -$87.3M | -$714.0M | -$415.9M |
| Cash | $240.6M | $530.2M | $568.5M | $1.3B |
| Long-term debt | $244.2M | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
NVAX Stock Sonar score 5/7 axes
Find similar shapesCompareNVAX ranks highest on growth (80th percentile) and institutional and government (73rd), and lowest on risk and compliance (4th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
